These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 12930892)

  • 21. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
    Peters PJ; Duenas-Decamp MJ; Sullivan WM; Brown R; Ankghuambom C; Luzuriaga K; Robinson J; Burton DR; Bell J; Simmonds P; Ball J; Clapham PR
    Retrovirology; 2008 Jan; 5():5. PubMed ID: 18205925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
    Wang T; Zhang Z; Wallace OB; Deshpande M; Fang H; Yang Z; Zadjura LM; Tweedie DL; Huang S; Zhao F; Ranadive S; Robinson BS; Gong YF; Ricarrdi K; Spicer TP; Deminie C; Rose R; Wang HG; Blair WS; Shi PY; Lin PF; Colonno RJ; Meanwell NA
    J Med Chem; 2003 Sep; 46(20):4236-9. PubMed ID: 13678401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.
    Reeves JD; Hibbitts S; Simmons G; McKnight A; Azevedo-Pereira JM; Moniz-Pereira J; Clapham PR
    J Virol; 1999 Sep; 73(9):7795-804. PubMed ID: 10438870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
    Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
    J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
    Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
    J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
    Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
    Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
    J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
    LaBonte JA; Madani N; Sodroski J
    J Virol; 2003 Jun; 77(12):6645-59. PubMed ID: 12767984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
    Chabot DJ; Zhang PF; Quinnan GV; Broder CC
    J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
    Locher CP; Witt SA; Kassel R; Dowell NL; Fujimura S; Levy JA
    J Gen Virol; 2005 Apr; 86(Pt 4):1171-1179. PubMed ID: 15784911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
    Lu L; Pan C; Li Y; Lu H; He W; Jiang S
    Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
    Nolan KM; Jordan AP; Hoxie JA
    J Virol; 2008 Jan; 82(2):664-73. PubMed ID: 17977968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.